# DFP-11207

Source: https://onco.cc/drugs/dfp-11207/  
OnCo record `dfp-11207` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DFP-11207 is an experimental small molecule from Delta-Fly Pharma, in phase 1 trials for solid tumours; its current status is not stated.

## Summary

DFP-11207 is a small molecule (oral, modified 5-FU) from Delta-Fly Pharma. An improved oral 5-FU designed to keep anti-tumour activity without causing a low platelet count. Its furthest stage is phase 1, for solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT02171221 in solid tumours COMPLETED; no later registered trial found. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: DFP-11207
- Modality: Small molecule (oral, modified 5-FU)
- Mechanism: An improved oral 5-FU designed to keep anti-tumour activity without causing a low platelet count.

## Sources

- Delta-Fly Pharma: delta-flypharma.co.jp: https://www.delta-flypharma.co.jp/en/r-and-d
- Delta-Fly Pharma: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT02171221
- ClinicalTrials.gov: trials of DFP-11207: https://clinicaltrials.gov/search?intr=DFP-11207

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Delta-Fly Pharma](https://onco.cc/companies/delta-fly-pharma/)
- trials: [Phase I Study of Oral DFP-11207 in Solid Tumors](https://onco.cc/trials/nct02171221/)

---
JSON: https://onco.cc/api/v1/entities/dfp-11207.json